BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ozeki I, Nakajima T, Suii H, Tatsumi R, Yamaguchi M, Arakawa T, Kuwata Y. Predictors of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting antiviral treatment: relationship with serum zinc. J Clin Biochem Nutr 2020;66:245-52. [PMID: 32523252 DOI: 10.3164/jcbn.19-98] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Harimoto N, Araki K, Muranushi R, Hoshino K, Yamanaka T, Hagiwara K, Ishii N, Tsukagoshi M, Watanabe A, Shirabe K. Significance of zinc deficiency in patients with hepatocellular carcinoma undergoing hepatic resection. Hepatol Res 2021. [PMID: 34761491 DOI: 10.1111/hepr.13730] [Reference Citation Analysis]
2 Váncsa S, Németh D, Hegyi P, Szakács Z, Farkas Á, Kiss S, Hegyi PJ, Kanjo A, Sarlós P, Erőss B, Pár G. Diabetes Mellitus Increases the Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Therapy: Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021;8:744512. [PMID: 34733865 DOI: 10.3389/fmed.2021.744512] [Reference Citation Analysis]
3 Li S, Huang J, Yang F, Zeng H, Tong Y, Li K. High expression of PARD3 predicts poor prognosis in hepatocellular carcinoma. Sci Rep 2021;11:11078. [PMID: 34040099 DOI: 10.1038/s41598-021-90507-w] [Reference Citation Analysis]
4 Kuwano A, Yada M, Nagasawa S, Tanaka K, Morita Y, Masumoto A, Motomura K. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment. J Viral Hepat 2021. [PMID: 34661320 DOI: 10.1111/jvh.13625] [Reference Citation Analysis]